Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$165.09M
304.69K shares · 0.1% of portfolio
UNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp (UTHR) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Silver Spring, United States and has 1,400 employees. The company is worth $25.08B and trades at 20.9x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $3.18B in fiscal 2025, up 10.6% from the year before. Net income was $1.33B. The share price is 4.0% below its 52-week high of $609.35. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $925.85M. In that quarter, 3 of them opened or added to the position and 4 reduced it. Over the last 30 days, company insiders sold $109.65M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +181.3% over 5Y.
today you would have $2,794.72▲ +179.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $487.25 | $352.84 | $219.89 | $278.09 | $216.08 | $151.79 | $88.08 | $108.90 | $147.95 | $143.43 | $156.61 | $129.49 | $113.08 | $53.42 | $47.25 | $63.22 | $52.65 | $31.27 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 19.3% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 15.1 across this company’s own years on record.
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GMABGenmab A/s | $40.00 | 31.5x | 4.0x | 0.00% | 14.00% | $24.6B |
| PHGKoninklijke Philips NV | $26.92 | 20.1x | 2.0x | 3.75% | 10.15% | $26.31B |
| INCYIncyte Corp | $116.93 | 14.5x | 3.7x | 0.00% | 30.67% | $23.7B |
| LHLabcorp Holdings Inc | $329.93 |
| P/E | 15.1x | 17.5x | 14.3x | 11.1x | 18.5x | 21.5x | 13.2x | — | 8.1x | 15.9x | 9.4x | 12.3x | 20.6x | 34.5x | 9.4x | 12.9x | 35.5x | 150.4x | — |
| P/S | 4.8x | 6.7x | 5.5x | 4.4x | 6.6x | 5.8x | 4.6x | 2.7x | 2.9x | 3.7x | 4.0x | 4.8x | 4.7x | 5.1x | 2.9x | 3.4x | 6.2x | 8.0x | 5.1x |
| P/B | 2.7x | 3.0x | 2.5x | 1.7x | 2.7x | 2.5x | 2.0x | 1.4x | 1.7x | 3.0x | 3.5x | 4.5x | 4.9x | 4.5x | 2.5x | 2.7x | 4.1x | 4.4x | 2.6x |
| EPS | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | -$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 | -$1.08 |
| Profit margin | 31.27% | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% | 44.45% | 26.40% | 15.63% | 33.23% | 29.32% | 17.86% | 5.42% | -17.52% |
| ROE | 17.50% | 18.81% | 18.55% | 16.46% | 15.16% | 12.02% | 15.16% | -3.76% | 21.13% | 19.88% | 38.55% | 41.02% | 27.37% | 13.86% | 28.09% | 22.97% | 11.98% | 2.98% | -8.88% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
+6.9% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 27.3x |
| 3.1x |
| 0.87% |
| 11.73% |
| $26.76B |
| DGXQuest Diagnostics Inc | $243.28 | 25.8x | 3.6x | 1.41% | 14.60% | $26.85B |
| ROIVRoivant Sciences Ltd. | $37.45 | — | 6.4x | 0.00% | -8.52% | $27.05B |
